GlassScriptPhysician profile
Stanley Glasser
NPI 1487694386
$4,681.19
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,593 · 2020: $704 · 2021: $384.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $534.99 | 2019-2020 | |
| Amgen INC. | $485.93 | 2019-2021 | |
| Glaxosmithkline, LLC. | $469.15 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $434.57 | 2019 | |
| Abbvie INC. | $293.99 | 2019-2021 | |
| Allergan, INC. | $281.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $220.17 | 2019-2020 | |
| Genzyme Corporation | $216.50 | 2019-2021 | |
| Lilly USA, LLC | $190.41 | 2019 | |
| Insmed, INC. | $168.71 | 2019 | |
| Merck Sharp & Dohme LLC | $140.47 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $133.01 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.16 | 2019-2020 | |
| Grifols USA, LLC | $125.00 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $117.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $107.24 | 2019-2021 | |
| Shire North American Group INC | $91.94 | 2019 | |
| Phadia US INC. | $50.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.74 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $37.78 | 2019 | |
| Mylan Specialty L.P. | $34.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.10 | 2021 | |
| Novo Nordisk INC | $23.83 | 2019 | |
| Electromed, INC. | $19.26 | 2019 | |
| Amarin Pharma, INC. | $14.44 | 2021 | |
| Philips North America LLC | $14.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Glasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.